Clinical Trial Data
-
Acoramidis Significantly Reduces Cardiovascular Mortality in ATTRibute-CM Open Label Extension Through 42 Months
BridgeBio Pharma’s acoramidis demonstrated a 44% reduction in cardiovascular mortality risk in ATTR-CM patients after 42 months in the ATTRibute-CM open label extension study. The study also showed a 46% hazard reduction in cardiovascular mortality or first cardiovascular hospitalization. Approximately 50% of participants exhibited disease stabilization compared to less than 20% on placebo at month 30. Acoramidis, marketed as Attruby® and BEYONTTRA®, exhibited the fastest benefit observed in a Phase 3 ATTR-CM study, with positive changes seen in 3 months.
